Vilket är priset för Xuanzhubio-b (2575)

Priset för Xuanzhubio-b (2575) är $1.35

Vilket är marknadsvärdet för Xuanzhubio-b (2575)

Marknadsvärdet för Xuanzhubio-b (2575) är $700.36M

Xuanzhubio-b (2575) Pris historia

Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.

År	Prestanda
2026 (TTM)	-41.43%
2025	0.00%

År

Prestanda

2026 (TTM)

-41.43%

2025

0.00%

Företag	Aktiekurs	Förändring 1år%	Land
MERCK Kommanditgesellschaft auf Aktien MER.SW	$171.67	-	DE
Merck KGaA MRK.DE	$166.36	31.46%	DE
Takeda Pharmaceutical Company Limited 4502.T	$37.84	25.87%	JP
Galderma Group AG GALD.SW	$222.33	27.49%	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$21.19	17.16%	IN

Företag

Aktiekurs

Förändring 1år%

Land